Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, 19 Applications Related to RNAi

Premium
Title: Methods and Reagents for Oligonucleotide Synthesis
 
Number: 7,205,399
 
Filed: July, 3, 2002
 
Lead Inventor: Chandra Vargeese, Sirna Therapeutics (Merck)
 
The invention “features novel compositions, linkers, derivatized solid supports, and methods for the efficient solid phase synthesis of oligonucleotides, including RNA, DNA, RNA-DNA chimeras, and analogs thereof,” according to the patent’s abstract.
 

 
Title: Recombinant DNA Constructs and Methods for Controlling Gene Expression
 
Numbers: 20070089196, 20070089195, 20070089194, 20070089193, 20070089192, 20070089191, 20070089190, 20070089189, 20070089188, 20070089187, 20070089186, 20070089185, 20070089184
 
Filed: Oct. 10, 2006
 
Lead Inventor: Shihshieh Huang, Monsanto
 
The invention “provides molecular constructs and methods for use thereof, including constructs including heterologous miRNA recognition sites, constructs for gene suppression including a gene suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence, constructs containing engineered miRNA or miRNA precursors, and constructs for suppression of production of mature microRNA in a cell,” the patent applications’ abstracts state. “Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use. The invention further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous, [as well as] … novel miRNAs and miRNA precursors from crop plants including maize and soy.”
 

 
Title: siRNA Targeting Complement Factor B
 
Numbers: 20070088154
 
Filed: Dec. 7, 2006
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
According to its abstract, the patent application claims that “efficient sequence-specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.”
 

 
Title: siRNA Targeting BCL2L1
 
Numbers: 20070088153
 
Filed: Dec. 7, 2006
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
According to its abstract, the patent application claims that “efficient sequence-specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.”
 

 
Title: siRNA Targeting KRAS
 
Numbers: 20070088152
 
Filed: Dec. 4, 2006
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
The patent application’s abstract states that “efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.”
 

 
Title: Methods of Treating Ocular Conditions
 
Numbers: 20070087989
 
Filed: Oct. 12, 2006
 
Lead Inventor: Andrew Huang, University of Minnesota
 
The invention “provides siRNA specific for myocilin and mutant myocilin, and methods of treating ocular conditions and/or diseases,” according to the patent application’s abstract.
 

 
Title: Method of Identifying Agents that Inhibit the Growth of Cancer Cells
 
Numbers: 20070087984
 
Filed: Aug. 24, 2004 PCT Filed: Aug. 24, 2004
 
Lead Inventor: Xiuyuan Hu, Immusol
 
The invention, the patent application’s abstract states, is “directed to methods of identifying agents useful for inhibiting cancer cells. The agents bind to one of the proteins described herein, or to a gene or mRNA encoding such protein. The invention is also directed to methods for inhibiting cancer cells by administering an agent that binds to one of the proteins described herein, or to a gene or mRNA encoding such protein.”
 

 
Title: Human microRNA Targets in HIV Genome and a Method of Identification Thereof
 
Numbers: 20070087335
 
Filed: Oct. 10, 2006
 
Lead Inventor: Samir Kumar Brahmachari, Institute of Genomics and Integrative Biology
 
According to its abstract, the patent application “relates to human microRNA targets in [the] HIV genome and a method of identification thereof. Using multiple software, targets to six human microRNAs were discovered in the net, vpr, env, and I vif genes. The miRNAs were identified as hsa-miR-29a, hsa-miR-29b, hsa-miR-29c, hsa-mir-149, hsa-mir-324-5p, [and] hsa-mir-378. These miRNAs or [their] homologues can be used as therapeutics against HIV infection,” the abstract states.
 
“The invention further relates to a novel strategy to target genes of HIV-1 by human microRNAs, or [their] homologues, to inactivate or block HIV activity,” it adds. “The computational approach towards identification of human miRNA targets in the HIV genome and the variation in the microRNA levels was further validated experimentally.”

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.